Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Katrin Fischhuber"'
Autor:
Katrin Fischhuber, Zoltán Bánki, Janine Kimpel, Natalie Kragl, Annika Rössler, Annika Bolze, Brigitte Muellauer, Joachim Angerer, Gábor Nagy, Eszter Nagy, Valeria Szijarto
Publikováno v:
Viruses, Vol 15, Iss 12, p 2300 (2023)
The Coronavirus Disease 2019 (COVID-19) pandemic and the subsequent increase in respiratory viral infections highlight the need for broad-spectrum antivirals to enable a quick and efficient reaction to current and emerging viral outbreaks. We previou
Externí odkaz:
https://doaj.org/article/2c1158ad329c428595b2674c2dfc0bf3
Autor:
Friedrich Erhart, Johanna Buchroithner, René Reitermaier, Katrin Fischhuber, Simone Klingenbrunner, Ido Sloma, Dror Hibsh, Renana Kozol, Sol Efroni, Gerda Ricken, Adelheid Wöhrer, Christine Haberler, Johannes Hainfellner, Günther Krumpl, Thomas Felzmann, Alexander M. Dohnal, Christine Marosi, Carmen Visus
Publikováno v:
Acta Neuropathologica Communications, Vol 6, Iss 1, Pp 1-14 (2018)
Abstract Audencel is a dendritic cell (DC)-based cellular cancer immunotherapy against glioblastoma multiforme (GBM). It is characterized by loading of DCs with autologous whole tumor lysate and in vitro maturation via “danger signals”. The recen
Externí odkaz:
https://doaj.org/article/31567993947f492daafe23f1e64695ff
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 8 (2020)
5′-AMP-activated protein kinase (AMPK) and the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) are main players in the cellular adaptive response to metabolic and oxidative/xenobiotic stress, respectively. AMPK does not only
Externí odkaz:
https://doaj.org/article/02129494df29457bb128401135ebf022
Publikováno v:
Redox Biology, Vol 29, Iss , Pp - (2020)
The transcription factor Nrf2 (nuclear factor (erythroid-derived 2)-like 2) and the kinase AMPK (AMP-activated protein kinase) participate in the cellular adaptive response to redox or energy stress. Despite accumulating evidence for positive coopera
Externí odkaz:
https://doaj.org/article/0a4e9d410c3d4c549c5a87c9997283e2
Autor:
Katrin Fischhuber, Daniela Lötsch, Walter Berger, Alexander M. Dohnal, Fernando J. Sialana, Gert Lubec, Bernadette Blauensteiner, Friedrich Erhart, Simone Klingenbrunner, Thomas Felzmann, Angela Halfmann, Tamara Weiss, René Reitermaier, Carmen Visus, Sabine Spiegl-Kreinecker
Publikováno v:
Cytotherapy. 21:643-658
Background Glioblastoma is the most aggressive type of brain cancer. Dendritic cell (DC)-based immunotherapy against glioblastoma depends on the effectiveness of loaded antigens. Sphere-inducing culture conditions are being studied by many as a poten
Autor:
Bernadette Blauensteiner, Dieter Printz, Katrin Fischhuber, René Reitermaier, Carmen Visus, Friedrich Erhart, Gabriel Zirkovits, Klara Soukup, Daniela Lötsch, Simone Klingenbrunner, Walter Berger, Sabine Spiegl-Kreinecker, Angela Halfmann, Alexander M. Dohnal
Publikováno v:
Journal of Cellular and Molecular Medicine
Glioblastoma is the most dangerous brain cancer. One reason for glioblastoma's aggressiveness are glioblastoma stem‐like cells. To target them, a number of markers have been proposed (CD133, CD44, CD15, A2B5, CD36, CXCR4, IL6R, L1CAM, and ITGA6). A
Autor:
Friedrich Erhart, Simone Klingenbrunner, Hannes Hahne, Adelheid Wöhrer, Sabine Spiegl-Kreinecker, Johanna Buchroithner, Walter Berger, Matthias Hackl, Gerda Ricken, René Reitermaier, Carmen Visus, Katrin Fischhuber, Daniela Lötsch, Christine Marosi, Chen Meng, Johannes A. Hainfellner, Georg Widhalm, Thomas Felzmann, Alexander M. Dohnal, Bernhard Kuster, Susanna Skalicky
Publikováno v:
NPJ Vaccines
npj Vaccines, Vol 5, Iss 1, Pp 1-13 (2020)
npj Vaccines, Vol 5, Iss 1, Pp 1-13 (2020)
Glioblastoma is the most prevalent and aggressive brain cancer. With a median overall survival of ~15–20 months under standard therapy, novel treatment approaches are desperately needed. A recent phase II clinical trial with a personalized immunoth
Autor:
Sol Efroni, Johannes A. Hainfellner, Alexander M. Dohnal, Adelheid Wöhrer, Christine Marosi, Thomas Felzmann, René Reitermaier, Friedrich Erhart, Carmen Visus, Simone Klingenbrunner, Katrin Fischhuber, Gerda Ricken, Christine Haberler, Dror Hibsh, Renana Kozol, Günther Krumpl, Johanna Buchroithner, Ido Sloma
Publikováno v:
Acta Neuropathologica Communications
Acta Neuropathologica Communications, Vol 6, Iss 1, Pp 1-14 (2018)
Acta Neuropathologica Communications, Vol 6, Iss 1, Pp 1-14 (2018)
Audencel is a dendritic cell (DC)-based cellular cancer immunotherapy against glioblastoma multiforme (GBM). It is characterized by loading of DCs with autologous whole tumor lysate and in vitro maturation via “danger signals”. The recent phase I
Publikováno v:
Biotechnology advances. 36(6)
Type 2 diabetes mellitus (DM) has reached pandemic proportions and effective prevention strategies are wanted. Its onset is accompanied by cellular distress, the nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor boosting cy
Autor:
Carmen Visus, Katrin Fischhuber, Simone Klingenbrunner, Rene Reitermaier, Heike Knausz, Friedrich Erhart, Sandra Moricz, Caterina Barresi, Thomas Felzmann
Publikováno v:
The Journal of Immunology. 192:206.1-206.1
Activartis is developing AV0113, an autologous dendritic cell (DC)-based cancer vaccine for glioblastoma multiforme (GBM). AV0113 is characterized by high release of IL-12, Th1 polarization and a potent anti-tumor immune response. A total of 78 GBM p